Myriad Genetics (MYGN) Current Leases (2019 - 2026)

Myriad Genetics has disclosed Current Leases across 8 years of filings, most recently posting $7.1 million for Q1 2026.

• In Q1 2026, Current Leases fell 34.86% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 34.86% YoY), while the FY2025 annual figure was $6.9 million, down 46.09% from the prior year.
• Current Leases climbed to $7.1 million in Q1 2026, from $6.9 million in the prior quarter.
• Over the last five years, Current Leases for MYGN reached as high as $17.8 million in Q3 2023 and fell as low as $6.9 million in Q4 2025.
• The 5-year median for Current Leases is $13.4 million (2022), against an average of $12.7 million.
• Annual changes were most pronounced in 2023 — Current Leases increased 27.82% — and 2025, when it slumped 46.09%.
• A 5-year view of Current Leases shows it stood at $14.1 million in 2022, then increased by 14.89% to $16.2 million in 2023, then retreated by 20.99% to $12.8 million in 2024, then tumbled by 46.09% to $6.9 million in 2025, then rose by 2.9% to $7.1 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $7.1 million, $6.9 million, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.